Equities analysts predict that Kindred Biosciences Inc (NASDAQ:KIN) will post earnings per share (EPS) of ($0.38) for the current quarter, according to Zacks. Two analysts have issued estimates for Kindred Biosciences’ earnings, with the lowest EPS estimate coming in at ($0.39) and the highest estimate coming in at ($0.36). Kindred Biosciences posted earnings per share of ($0.46) during the same quarter last year, which indicates a positive year over year growth rate of 17.4%. The firm is expected to announce its next quarterly earnings report on Wednesday, March 4th.

According to Zacks, analysts expect that Kindred Biosciences will report full year earnings of ($1.58) per share for the current financial year, with EPS estimates ranging from ($1.62) to ($1.55). For the next financial year, analysts expect that the business will post earnings of ($1.39) per share, with EPS estimates ranging from ($1.47) to ($1.31). Zacks Investment Research’s EPS averages are a mean average based on a survey of analysts that that provide coverage for Kindred Biosciences.

Kindred Biosciences (NASDAQ:KIN) last announced its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.39) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.37) by ($0.02). The firm had revenue of $1.10 million during the quarter, compared to analyst estimates of $1.55 million. Kindred Biosciences had a negative return on equity of 58.86% and a negative net margin of 1,461.28%.

Several equities analysts have recently issued reports on KIN shares. Zacks Investment Research upgraded Kindred Biosciences from a “sell” rating to a “hold” rating in a research report on Saturday, November 16th. HC Wainwright restated a “buy” rating and issued a $16.00 target price (down previously from $17.50) on shares of Kindred Biosciences in a research note on Wednesday, November 13th. BidaskClub cut Kindred Biosciences from a “hold” rating to a “sell” rating in a research note on Tuesday, February 4th. Finally, ValuEngine upgraded Kindred Biosciences from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, December 3rd. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $13.94.

Kindred Biosciences stock opened at $9.28 on Friday. The firm has a market capitalization of $367.65 million, a P/E ratio of -5.66 and a beta of 0.30. Kindred Biosciences has a 1 year low of $5.96 and a 1 year high of $11.35. The business has a 50-day moving average of $9.32 and a 200-day moving average of $8.01. The company has a current ratio of 9.30, a quick ratio of 8.88 and a debt-to-equity ratio of 0.21.

A number of institutional investors have recently made changes to their positions in the business. Teton Advisors Inc. grew its stake in Kindred Biosciences by 5.9% in the third quarter. Teton Advisors Inc. now owns 36,000 shares of the biopharmaceutical company’s stock valued at $247,000 after acquiring an additional 2,000 shares during the period. Gabelli Funds LLC lifted its holdings in shares of Kindred Biosciences by 23.1% in the third quarter. Gabelli Funds LLC now owns 16,000 shares of the biopharmaceutical company’s stock valued at $110,000 after purchasing an additional 3,000 shares in the last quarter. Bank of Montreal Can lifted its holdings in Kindred Biosciences by 99.5% during the fourth quarter. Bank of Montreal Can now owns 6,474 shares of the biopharmaceutical company’s stock worth $55,000 after acquiring an additional 3,229 shares during the period. Citigroup Inc. lifted its holdings in Kindred Biosciences by 84.3% during the fourth quarter. Citigroup Inc. now owns 8,159 shares of the biopharmaceutical company’s stock worth $69,000 after acquiring an additional 3,732 shares during the period. Finally, Metropolitan Life Insurance Co NY lifted its holdings in Kindred Biosciences by 44.5% during the third quarter. Metropolitan Life Insurance Co NY now owns 13,940 shares of the biopharmaceutical company’s stock worth $95,000 after acquiring an additional 4,293 shares during the period. 67.16% of the stock is owned by hedge funds and other institutional investors.

Kindred Biosciences Company Profile

Kindred Biosciences, Inc, a commercial-stage biopharmaceutical company, focusing on developing therapies for pets. Its product pipeline consists of small molecules and biologics for a range of indications in dogs, cats, and horses. The company offers Mirataz, a mirtazapine transdermal ointment for the management of weight loss in cats.

See Also: How is the discount rate different from the Federal Funds rate?

Get a free copy of the Zacks research report on Kindred Biosciences (KIN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Kindred Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kindred Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.